Rega marang bathi mangsa ngarep: Intellia Corp (NTLA)

NTLA (Intellia) - tandha merek perusahaan

Anticipation of the Phase 2 CRISPR trial results is driving the current trend, while the forward P/E ratio history of Intellia Therapeutics (NTLA) demonstrates a valuation adaptation to the cycle. 0.00 becomes the new value for this metric. Strategic alliances with biotech behemoths are accelerating drug development, and its first-mover status in gene editing will provide Intellia Therapeutics (NTLA) with the exclusive pricing power to set premium therapy costs in the future.

Rega marang bathi mangsa ngarep: intelliatx.com (NTLA) kanggo 04.07.2022 - 16.11.2026

Rincian analitis perusahaan Intellia Therapeutics

- indikator kapitalisasi bursa perusahaan:
Produk merek intelliatx.com

Forward P/E compares the current market value of a business with projected net income for a future period. For Intellia Therapeutics (NTLA), this ratio reflects market expectations regarding the monetization of in vivo CRISPR therapies. By analyzing the forward P/E dynamics of the company, an investor can identify whether the asset is overbought or determine an optimal entry point. Inelastic demand for the treatment of rare pathologies justifies a high earnings premium. This metric serves as a filter between speculative hype and genuine fundamental growth.

Pesaing wigati

Prakiraan rega marang bathi TEM (Tempus AI, Inc)|Qiagen Group (QGEN) - Pangali forward rega marang bathi|Rega marang bathi mangsa ngarep ionispharma.com IONS|Kapitalisasi marang proyeksi bathi Repligen Corporation (RGEN)|RNA: Prakiraan rega marang bathi|Pangali mangsa ngarep rega marang bathi CRSP (CRISPR Therapeutics Corp)|WGS: Pangali Forward P/E|Rasio prakiraan rega marang bathi Ultragenyx Corp (RARE)|BEAM (Beam Therapeutics Inc) - Pangali Forward P/E|SRPT: Pangali mangsa ngarep rega marang bathi|Rega marang bathi mangsa ngarep Twist Bioscience Corp (TWST)|Prakiraan rega marang bathi 10x Genomics Inc TXG|Rega marang bathi mangsa ngarep Stoke STOK|BioLife (BLFS) - Rasio prakiraan rega marang bathi|wavelifesciences.com - Pangali Forward P/E|Rasio rega marang bathi sing dikarepake MAZE|SION: Pangali Forward P/E|PRME - Kapitalisasi marang proyeksi bathi|Prakiraan rega marang bathi TSHA|QURE - Pangali forward rega marang bathi|Pangali Forward P/E MGTX|Kapitalisasi marang proyeksi bathi regenxbio.com|Pangali Forward P/E SLDB (Solid Biosciences Inc)|OCGN: Rasio rega marang bathi mangsa ngarep|PACB - Rega marang bathi mangsa ngarep|Benitec (BNTC) - Prakiraan rega marang bathi|DSGN: Pangali Forward P/E|RCKT: Rasio kapitalisasi marang bathi mangsa ngarep|FDMT (4D Molecular Therapeutics, Inc.) - Pangali Forward P/E|lexeotx.com (LXEO) - Kapitalisasi marang proyeksi bathi|Pangali Forward P/E KRRO|Prakiraan rega marang bathi Editas Medicine, Inc. EDIT|Rega marang bathi mangsa ngarep silence-therapeutics.com SLN|PRQR: Rasio rega marang bathi mangsa ngarep|CDXS - Rega marang bathi mangsa ngarep|Kapitalisasi marang proyeksi bathi Sangamo Therapeutics, Inc. SGMO|NAUT (nautilus.bio) - Prakiraan rega marang bathi|Rasio prakiraan rega marang bathi Metagenomi, Inc. (MGX)|Prakiraan rega marang bathi DTIL|Rasio rega marang bathi mangsa ngarep GBIO (generationbio.com)|Rega marang bathi mangsa ngarep Boundless Bio, Inc (BOLD)|Pangali Forward P/E Exicure Inc. (XCUR)|Imunon, Inc. - Prakiraan rega marang bathi|PHIO: Rasio rega marang bathi mangsa ngarep|MBIO - Rega marang bathi mangsa ngarep|Rasio rega marang bathi sing dikarepake RNAZ|Bionano Genomics, Inc. (BNGO) - Rega marang bathi mangsa ngarep|Applied DNA Sciences, Inc. (APDN) - Pangali Forward P/E|BLUE (bluebirdbio.com) - Pangali Forward P/E|Rasio rega marang bathi mangsa ngarep IPA (ImmunoPrecise Antibodies)|Pangali Forward P/E OMGA|Prakiraan rega marang bathi Singular Genomics Systems OMIC|Pangali Forward P/E RGLS (regulusrx.com)|Syros Pharmaceuticals Inc. (SYRS) - Rasio prakiraan rega marang bathi|TBIO: Prakiraan rega marang bathi|Pangali mangsa ngarep rega marang bathi TCON (TRACON)|UBX: Pangali Forward P/E